株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州・中東・アフリカにおける癌の生物学的治療市場

Europe, Middle East and Africa Cancer Biological Therapy Market - Estimation & Forecast, 2013-2023

発行 Market Research Future 商品コード 522793
出版日 ページ情報 英文 88 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
欧州・中東・アフリカにおける癌の生物学的治療市場 Europe, Middle East and Africa Cancer Biological Therapy Market - Estimation & Forecast, 2013-2023
出版日: 2017年04月20日 ページ情報: 英文 88 Pages
概要

当レポートでは、欧州・中東・アフリカにおける癌の生物学的治療市場について調査し、治療タイプ・エンドユーザー・地域/国別の市場動向、収益・成長率の推移と予測、市場シェアの分析、市場の促進・阻害要因ならびに市場機会、競合情勢や主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 調査範囲

第2章 イントロダクション

第3章 調査手法

第4章 市場力学

  • イントロダクション
  • 促進要因
    • 癌生存率の上昇
    • 先端医療の需要増加
    • 副作用の低減
    • 中東・アフリカ地域における生活習慣の変化と喫煙人口の増加
  • 阻害要因
    • 高額な医療費
  • 課題
    • 競合の激化

第5章 市場分析

  • ファイブフォース分析

第6章 欧州・中東・アフリカにおける癌の生物学的治療市場:治療タイプ別

  • イントロダクション
  • モノクローナル抗体
  • 抗体-薬物複合体
  • 受容体阻害薬
  • インターフェロン
  • インターロイキン
  • 遺伝子治療
  • ドラッグデリバリー
  • コロニー刺激因子
  • 癌ワクチン
  • その他

第7章 欧州・中東・アフリカにおける癌の生物学的治療市場:エンドユーザー別

  • イントロダクション
  • 病院 & 診療所
  • 研究所
  • 癌センター
  • その他

第8章 欧州・中東・アフリカにおける癌の生物学的治療市場:地域別

  • イントロダクション
  • 欧州
    • 西欧
      • ドイツ
      • フランス
      • イタリア
      • スペイン
    • その他の欧州諸国
  • 中東
    • カタール
    • UAE
    • クウェート
    • バーレーン
    • オマーン
    • サウジアラビア

第9章 競合情勢

  • 企業の市場シェア分析

第10章 企業プロファイル

  • Amgen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • EnGeneIC Ltd.
  • EnGeneIC Ltd.
  • EnGeneIC Ltd.
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.,
  • Novartis
  • Pfizer Inc,
  • Seattle Genetics Inc.
  • Teva Pharmaceutical Industries Ltd.

図表一覧

目次

Introduction:

Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use.

Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the body's immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies.

The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period.

EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon.

On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015.

On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.

Key Players:

The leading market players in the Europe, Middle East and Africa Cancer Biological Therapy market include Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, EnGeneIC Ltd., EnGeneIC Ltd., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis, Pfizer Inc, Seattle Genetics Inc. and Teva Pharmaceutical Industries Ltd.

Study objectives of Cancer Biological Therapy market:

  • To provide insights about factors influencing and affecting the market growth
  • To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
  • To provide historical and forecast revenue of the market segments based on type of therapy, end users, and its sub-segments.
  • To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

Target Audience:

  • Medical devices distributors
  • Hospitals & Clinics
  • Potential investors
  • Key executive (CEO and COO) and strategy growth manager
  • Pharmaceutical companies

Key Findings:

  • Europe accounted for the largest market share of monoclonal antibodies cancer biological therapy market, registering $5,316.8 million in 2015 and expected to reach at $6,844.1 million by 2021
  • Targeted Therapy is the fastest growing segment with a CAGR of and 5.7% in EMEA
  • Cancer growth blockers is contributing remarkable share towards the market registering $4,990.5 million in 2015

The reports also covers regional analysis:

  • Europe
  • Western Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
  • Middle East
  • Gulf Cooperation Council (GCC)
  • Qatar
  • UAE
  • Kuwait
  • Bahrain
  • Oman
  • Saudi Arabia
  • Rest of Middle East
  • Africa

Table of Contents

1. Report Prologue

2. Market Introduction

  • 2.1. Definition
  • 2.2. Scope of Study
  • 2.3. Research Objective
  • 2.4. Assumptions & Limitations
    • 2.4.1. Assumptions
    • 2.4.2. Limitations
  • 2.5. Market Structure

3. Research Methodology

  • 3.1. Research Process
  • 3.2. Primary Research
  • 3.3. Secondary Research

4. Market Dynamics

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Increasing Cancer Survival Rate
    • 4.2.2. Growing demand for advanced therapies
    • 4.2.3. Less number of side effects as compared to conventional treatment methods
    • 4.2.4. Changing lifestyle and increasing smoking population in Middle East & Africa
  • 4.3. Restraints
    • 4.3.1. High cost of Cancer biological therapy
  • 4.4. Opportunities
    • 4.4.1. Untapped types of Cancers
  • 4.5. Challenges
    • 4.5.1. Strong competition

5. Market Factor Analysis

  • 5.1. Porter's Five Forces Model
    • 5.1.1. Bargaining power of suppliers
    • 5.1.2. Bargaining Power of Buyers
    • 5.1.3. Threat of New Entrants
    • 5.1.4. Threat of Substitutes
    • 5.1.5. Intensity of Rivalry

6. Europe, Middle East and Africa Respiratory Inhalers Market, By Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Conjugated Monoclonal Antibodies
  • 6.4. Cancer Growth Blockers
  • 6.5. Interferons
  • 6.6. Interleukins
  • 6.7. Gene Therapy
  • 6.8. Targeted Drug Delivery
  • 6.9. Colony Stimulating Factor
  • 6.10. Cancer Vaccines
  • 6.11. Others.

8. Europe, Middle East and Africa Cancer Biological Therapy Market, By End User

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Laboratories
  • 8.4. Cancer Research Centers
  • 8.5. Others

9. Europe, Middle East and Africa Cancer Biological Therapy Market, By Region

  • 9.1. Introduction
  • 9.2. Europe
    • 9.2.1. Western Europe
      • 9.2.1.1Germany
      • 9.2.1.2. France
      • 9.2.1.3. UK
      • 9.2.1.4. Italy
      • 9.2.1.5. Spain
    • 9.2.2. Rest Of Europe
  • 9.2. Middle East
      • 9.2.2.1. Qatar
      • 9.2.2.2. UAE
      • 9.2.2.3. Kuwait
      • 9.2.2.4. Bahrain
      • 9.2.2.5. Oman
      • 9.2.2.6. Saudi Arabia

10. Competitive Landscape

  • 10.1. Company Share Analysis

12. Company Profiles

  • 11.1. Amgen Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Product/Business Overview
    • 11.1.3. Adherium Health: Financials
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Bristol-Myers Squibb
    • 11.2.1. Company Overview
    • 11.2.2. Product overview
    • 11.2.3. Financial Overview
    • 11.2.4. Key Developments
    • 11.2.5. SWOT Analysis
  • 11.3. Celgene Corporation
    • 11.3.1. Company Overview
    • 11.3.2. Product Overview
    • 11.3.3. Financial Overview
    • 11.3.4. Key Development
    • 11.3.5. SWOT Analysis
  • 11.4. ELI Lilly and Company
    • 11.4.1. Company Overview
    • 11.4.2. Product Overview
    • 11.4.3. Financial Overview
    • 11.4.4. Key Developments
    • 11.4.5. SWOT Analysis
  • 11.5. EnGeneIC Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Product overview
    • 11.5.3. Financial Overview
    • 11.5.4. Key Developments
    • 11.5.5. SWOT Analysis
  • 11.6. EnGeneIC Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Product Overview
    • 11.6.3. Propeller Health: Financials
    • 11.6.4. Key Developments
    • 11.6.5. SWOT Analysis
  • 11.7. EnGeneIC Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Product Overview
    • 11.7.3. Financial Overview
    • 11.7.4. Key Developments
    • 11.7.5. SWOT Analysis
  • 11.8. F. Hoffmann-La Roche AG
    • 11.8.1. Company Overview
    • 11.8.2. Product Overview
    • 11.8.3. Financial Overview
    • 11.8.4. Key Developments
    • 11.8.5. SWOT Analysis
  • 11.9. Merck & Co. Inc.,
    • 11.9.1. Company Overview
    • 11.9.2. Product Overview
    • 11.9.3. Financial Overview
    • 11.9.4. Key Developments
    • 11.9.5. SWOT Analysis
  • 11.10. Novartis
    • 11.10.1. Company Overview
    • 11.10.2. Product Overview
    • 11.10.3. Financial Overview
    • 11.10.4. Key Developments
    • 11.10.5. SWOT Analysis
  • 11.11. Pfizer Inc,
    • 11.11.1. Company Overview
    • 11.11.2. Product Overview
    • 11.11.3. Financial Overview
    • 11.11.4. Key Developments
    • 11.11.5. SWOT Analysis
  • 11.12. Seattle Genetics Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Product Overview
    • 11.12.3. Financial Overview
    • 11.12.4. Key Developments
    • 11.12.5. SWOT Analysis
  • 11.13. Teva Pharmaceutical Industries Ltd.
    • 11.13.1. Company Overview
    • 11.13.2. Product Overview
    • 11.13.3. Financial Overview
    • 11.13.4. Key Developments
    • 11.13.5. SWOT Analysis

List of Tables

  • TABLE 1: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 2: MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2013-2021 (USD MILLION)
  • TABLE 3: INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 4: INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 5: CANCER GROWTH INHIBITORS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 6: GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY region 2013-2021 (USD MILLION)
  • TABLE 8: TARGETED DRUG DELIVERY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 9: CANCER VACCINES FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 1: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY END-USERS 2013-2021 (USD MILLION)
  • TABLE 11: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USD MILLION)
  • TABLE 16: FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 18: U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 19: ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 25: MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY, 2013-2021, (USD MILLION)
  • TABLE 30: GULF COOPERATION COUNCIL (GCC) CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 31: GULF COOPERATION COUNCIL (GCC)CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 32: QATAR CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USDMILLION)
  • TABLE 33: QATAR CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 34: UAE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 35: UAE CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 36: KUWAIT CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 37: KUWAIT CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 38: BAHRAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 39: BAHRAIN CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 40: OMAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 41: OMAN CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 42: SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 43: SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 44: REST OF MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 45: REST OF MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)
  • TABLE 46: AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 47: AFRICA CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD MILLION)

List of Figures

  • FIGURE 1: RESEARCH PROCESS
  • FIGURE 2: TOP-DOWN & BOTTOM-UP APPRAOCH
  • FIGURE 3: MARKET DYNAMICS FOR EMEA CANCER BIOLOGICAL THERAPY MARKET
  • FIGURE 4: ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2012 (%)
  • FIGURE 5: CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS
  • FIGURE 6: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE
  • FIGURE 7: MONOCLONAL ANTIBODIES MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 8: INTERFERONS MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 9: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY END-USERS
  • FIGURE 10: EMEA CANCER BIOLOGICAL THERAPY MARKET, BY REGION
  • FIGURE 11: EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 12: EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 13: EUROPE CANCER BIOLOGICAL THERAPY BY TYPES, 2013-2021 (USD MILLION)
  • FIGURE 14: EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 15: MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY, 2015 (USD MILLION)
  • FIGURE 16: QATAR: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 17: UAE: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 18: KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 19: BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 20: OMAN: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 21: SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%)
  • FIGURE 22: MIDDLE EAST CANCER BIOLOGICALTHERAPY MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 23: MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END-USERS, 2015 (USD MILLION)
  • FIGURE 24: AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 25: AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2015 (USD MILLION)
  • FIGURE 26: EMEA CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2015 (%)
Back to Top